{"id":"W2983703208","doi":"10.1093/neuonc/noz175.012","title":"ATIM-12. AVELUMAB IN NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME-THE SEJ STUDY","year":2019,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa; Ottawa Hospital; Clinique Neuro-Outaouais","funders":"","keywords":"Avelumab; Temozolomide; Medicine; Radiation therapy; Oncology; Internal medicine; Glioblastoma; Interim analysis; Immunotherapy; Clinical trial; Nivolumab; Cancer research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001887517,0.0005358311,0.001192006,0.0003116924,0.0002533046,0.000851654,0.0004718791,0.0007668388,0.002087001],"category_scores_gemma":[0.000667567,0.000249653,0.001406937,0.0004308354,0.0003710876,0.0005722765,0.0002937535,0.001171997,0.000497141],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005567176,"about_ca_system_score_gemma":0.001071606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001166244,"about_ca_topic_score_gemma":0.003240845,"domain_scores_codex":[0.9994926,0.0002637841,0.00003297548,0.00006024121,0.0000539266,0.00009628998],"domain_scores_gemma":[0.9993538,0.00008698182,0.000131667,0.00006338783,0.00005547407,0.0003086727],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6948391,0.02275651,0.1002759,0.002268879,0.007559051,0.001177254,0.0003142049,0.001466963,0.02320989,0.0007036913,0.009116535,0.136312],"study_design_scores_gemma":[0.3516138,0.3448749,0.2672338,0.0002156794,0.005206595,0.001256042,0.0002506876,0.001439913,0.005746823,0.0005365,0.02154639,0.00007878228],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901714,0.004364534,0.0001671248,0.0005600209,0.0001461122,0.0006526934,0.001572561,0.00002304698,0.002342602],"genre_scores_gemma":[0.9901809,0.002584351,0.0004447706,0.0006487236,0.0002337368,0.0005832024,0.002252172,0.00001136781,0.003060888],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002087001,"threshold_uncertainty_score":0.009982228,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01701592231573077,"score_gpt":0.2967068258603395,"score_spread":0.2796909035446087,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}